2.11
price down icon4.09%   -0.09
after-market After Hours: 2.11
loading
Nkarta Inc stock is traded at $2.11, with a volume of 455.99K. It is down -4.09% in the last 24 hours and up +47.55% over the past month. Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
See More
Previous Close:
$2.20
Open:
$2.15
24h Volume:
455.99K
Relative Volume:
0.33
Market Cap:
$131.27M
Revenue:
-
Net Income/Loss:
$-117.50M
P/E Ratio:
-0.8792
EPS:
-2.4
Net Cash Flow:
$-114.31M
1W Performance:
+16.57%
1M Performance:
+47.55%
6M Performance:
-36.64%
1Y Performance:
-69.06%
1-Day Range:
Value
$2.045
$2.15
1-Week Range:
Value
$1.78
$2.28
52-Week Range:
Value
$1.31
$8.33

Nkarta Inc Stock (NKTX) Company Profile

Name
Name
Nkarta Inc
Name
Phone
(925) 407-1049
Name
Address
1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO
Name
Employee
157
Name
Twitter
Name
Next Earnings Date
2025-03-26
Name
Latest SEC Filings
Name
NKTX's Discussions on Twitter

Compare NKTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
NKTX
Nkarta Inc
2.11 131.27M 0 -117.50M -114.31M -2.40
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Nkarta Inc Stock (NKTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-09-24 Initiated Rodman & Renshaw Buy
Aug-14-24 Upgrade Raymond James Outperform → Strong Buy
Mar-22-24 Downgrade Raymond James Strong Buy → Outperform
Dec-22-22 Downgrade Oppenheimer Outperform → Perform
Oct-10-22 Initiated Canaccord Genuity Buy
Jul-28-22 Initiated Needham Buy
Jul-18-22 Initiated SVB Leerink Outperform
Mar-11-22 Initiated Raymond James Outperform
Mar-08-22 Initiated H.C. Wainwright Buy
Jan-06-22 Initiated William Blair Outperform
Nov-18-21 Initiated SMBC Nikko Outperform
Jul-16-21 Initiated Oppenheimer Outperform
Aug-04-20 Initiated Cowen Outperform
Aug-04-20 Initiated Evercore ISI Outperform
Aug-04-20 Initiated Mizuho Buy
Aug-04-20 Initiated Stifel Buy
View All

Nkarta Inc Stock (NKTX) Latest News

pulisher
Apr 24, 2025

A stock that deserves closer examination: Estrella Immunopharma Inc (ESLA) - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

Technical analysis of Nkarta Inc (NKTX) stock chart patterns - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

Market Momentum Report: Nkarta Inc (NKTX)’s Negative Close at 2.18 - DWinneX

Apr 24, 2025
pulisher
Apr 23, 2025

Insider Sale Alert: Nkarta Inc [NKTX] – Is it Time to sell? - knoxdaily.com

Apr 23, 2025
pulisher
Apr 23, 2025

A Tale of Resilience: Nkarta Inc Amid Stock Market Turbulence - investchronicle.com

Apr 23, 2025
pulisher
Apr 21, 2025

Nkarta, Inc. (NASDAQ:NKTX) Receives Average Rating of “Buy” from Brokerages - Defense World

Apr 21, 2025
pulisher
Apr 18, 2025

JPMorgan Chase & Co. Raises Stock Position in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 18, 2025
pulisher
Apr 16, 2025

Layoff Tracker: Mural Oncology Cuts 90% of Staff, Explores Strategic Alternatives - BioSpace

Apr 16, 2025
pulisher
Apr 15, 2025

Nkarta (NKTX) Upgraded to Buy: Here's Why - NewsBreak: Local News & Alerts

Apr 15, 2025
pulisher
Apr 15, 2025

Wellington Management Group LLP Boosts Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Natural Killer Cell Therapy Market Hits New High | Major Giants Nkarta Therapeutics, Kiadis Pharma - newstrail.com

Apr 14, 2025
pulisher
Apr 14, 2025

American Century Companies Inc. Buys 7,378 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

Sei Investments Co. Invests $57,000 in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 13, 2025
pulisher
Apr 12, 2025

Nkarta’s (NKTX) Buy Rating Reiterated at Needham & Company LLC - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

Nkarta (NASDAQ:NKTX) Earns "Buy" Rating from Needham & Company LLC - MarketBeat

Apr 11, 2025
pulisher
Apr 11, 2025

Prudential Financial Inc. Sells 49,500 Shares of Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 11, 2025
pulisher
Apr 10, 2025

CAR NK Expert With 25-Year Track Record Strengthens Senti Bio's Scientific Leadership - Stock Titan

Apr 10, 2025
pulisher
Apr 05, 2025

Thrivent Financial for Lutherans Makes New Investment in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 05, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Cuts Stock Holdings in Nkarta, Inc. (NASDAQ:NKTX) - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Nkarta to Participate in an April Investor Conference - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

Leerink Partnrs Has Bullish Outlook for Nkarta Q1 Earnings - The AM Reporter

Apr 01, 2025
pulisher
Mar 31, 2025

Nkarta: Grinding Lower, Trying To Find Support (NASDAQ:NKTX) - Seeking Alpha

Mar 31, 2025
pulisher
Mar 31, 2025

Nkarta: Betting On The Turnaround (NASDAQ:NKTX) - Seeking Alpha

Mar 31, 2025
pulisher
Mar 31, 2025

What is HC Wainwright’s Forecast for Nkarta Q1 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

William Blair Estimates Nkarta’s Q1 Earnings (NASDAQ:NKTX) - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

Nkarta, Inc. (NASDAQ:NKTX) Receives $14.86 Average Price Target from Brokerages - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Stifel Nicolaus Has Lowered Expectations for Nkarta (NASDAQ:NKTX) Stock Price - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

What is HC Wainwright’s Forecast for Nkarta Q4 Earnings? - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

Needham & Company LLC Reaffirms “Buy” Rating for Nkarta (NASDAQ:NKTX) - Defense World

Mar 29, 2025
pulisher
Mar 27, 2025

Nkarta’s Strategic Workforce Reduction and Clinical Progress Justify Buy Rating - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı

Mar 27, 2025
pulisher
Mar 27, 2025

Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday? - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR), Perspective Therapeutics (CATX) and Nkarta (NKTX) - The Globe and Mail

Mar 27, 2025
pulisher
Mar 27, 2025

Nkarta to lay off staff, senior leadership, in bid to advance autoimmune cell therapy - BioPharma Dive

Mar 27, 2025
pulisher
Mar 27, 2025

Stifel cuts Nkarta stock price target to $14, maintains buy rating - Investing.com India

Mar 27, 2025
pulisher
Mar 27, 2025

Nkarta to lay off 34% of staff; Savara’s debt financing deal - Endpoints News

Mar 27, 2025
pulisher
Mar 27, 2025

H.C. Wainwright maintains Buy on Nkarta stock with $18 target By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

H.C. Wainwright maintains Buy on Nkarta stock with $18 target - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Nkarta lays off 3rd of staff to fund autoimmune CAR NK program - Fierce Biotech

Mar 27, 2025
pulisher
Mar 27, 2025

Newly pivoted to autoimmune, Nkarta trims staff by over third - FirstWord Pharma

Mar 27, 2025
pulisher
Mar 27, 2025

Nkarta’s Strategic Restructuring and NKX019 Progress Drive Buy Rating - TipRanks

Mar 27, 2025
pulisher
Mar 26, 2025

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights - GlobeNewswire

Mar 26, 2025
pulisher
Mar 26, 2025

Nkarta Posts Narrower Q4 Loss; Discloses Restructuring Plan - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

Nkarta Announces Major Restructuring and Leadership Changes - TipRanks

Mar 26, 2025
pulisher
Mar 26, 2025

Nkarta Inc To Reduce Workforce By 34%, Impacting 53 PositionsSEC Filing - MarketScreener

Mar 26, 2025
pulisher
Mar 26, 2025

Nkarta Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 26, 2025
pulisher
Mar 26, 2025

Nkarta's Strategic Reset: 34% Staff Cut Powers 5-Year Cash Runway with $380M War Chest - Stock Titan

Mar 26, 2025

Nkarta Inc Stock (NKTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Nkarta Inc Stock (NKTX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Levin Alyssa
See Remarks
Jan 15 '25
Sale
2.20
5,838
12,844
102,662
Brandenberger Ralph
Chief Technical Officer
Jan 15 '25
Sale
2.20
7,447
16,383
124,796
HASTINGS PAUL J
Chief Executive Officer
Jan 15 '25
Sale
2.20
17,378
38,232
319,859
Hager Alicia J.
Chief Legal Officer
Jan 15 '25
Sale
2.20
9,584
21,085
146,735
Hager Alicia J.
Chief Legal Officer
Jul 16 '24
Sale
8.00
3,396
27,168
103,819
Trager James
Chief Scientific Officer
Jun 18 '24
Sale
5.60
456
2,554
150,959
HASTINGS PAUL J
Chief Executive Officer
Jun 18 '24
Sale
5.60
1,770
9,912
240,737
Shook David
Chief Medical Officer
Jun 18 '24
Sale
5.60
456
2,554
116,524
Hager Alicia J.
Chief Legal Officer
Jun 18 '24
Sale
5.60
727
4,071
107,215
Brandenberger Ralph
Chief Technical Officer
Jun 18 '24
Sale
5.60
229
1,282
79,743
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):